What is TNK (Tenecteplase)?
TNK (tenecteplase) is a genetically engineered fibrinolytic agent—a modified version of tissue plasminogen activator (tPA/alteplase)—used primarily for thrombolysis in ST-elevation myocardial infarction (STEMI) and increasingly for acute ischemic stroke. 1, 2
Molecular Structure and Mechanism
Tenecteplase is a 527-amino acid glycoprotein created through specific genetic modifications to native alteplase 2:
- Substitution of threonine 103 with asparagine (kringle 1 domain)
- Substitution of asparagine 117 with glutamine (kringle 1 domain)
- Tetra-alanine substitution at amino acids 296-299 (protease domain)
These modifications result in superior pharmacologic properties compared to alteplase 1, 3:
- 14-fold greater fibrin specificity
- 80-fold greater resistance to plasminogen activator inhibitor-1 (PAI-1)
- 6-fold longer plasma half-life (approximately 18-22 minutes vs. 3.5 minutes for alteplase)
The mechanism involves binding to fibrin and converting plasminogen to plasmin, which dissolves blood clots. The enhanced fibrin specificity means more targeted clot dissolution with less systemic plasminogen activation and reduced circulating fibrinogen degradation 2.
Clinical Applications
STEMI (Primary FDA-Approved Indication)
Tenecteplase is administered as a single weight-based IV bolus for STEMI when primary PCI cannot be achieved within 2 hours of first medical contact 1, 4:
| Weight | Dose |
|---|---|
| <60 kg | 30 mg |
| 60-69 kg | 35 mg |
| 70-79 kg | 40 mg |
| 80-89 kg | 45 mg |
| ≥90 kg | 50 mg |
In the landmark ASSENT-2 trial, tenecteplase demonstrated equivalent 30-day mortality to alteplase but with significantly reduced noncerebral bleeding complications 1. The single-bolus administration (over 5-10 seconds) offers substantial practical advantages over alteplase's 90-minute infusion regimen 1, 4.
Acute Ischemic Stroke (Emerging Use)
While not yet universally FDA-approved for stroke, tenecteplase is increasingly used off-label and included in stroke guidelines 5, 6:
- Dose: 0.25 mg/kg (most commonly studied and recommended)
- Time window: Within 4.5 hours of symptom onset
- Meta-analyses demonstrate superior recanalization of large vessel occlusions compared to alteplase
- Noninferior for 3-month disability-free outcomes without increased symptomatic intracranial hemorrhage 6, 7
The 0.25 mg/kg dose appears optimal—no advantage has been demonstrated with higher doses (0.4-0.5 mg/kg) 6.
Key Advantages Over Alteplase
- Single-bolus administration (5-10 seconds vs. 90-minute infusion)
- Reduced noncerebral bleeding in STEMI trials 1
- Superior large vessel recanalization in stroke 6
- Lower cost and easier logistics 8
- No need for infusion pumps or weight-based calculations during administration
Critical Safety Considerations
Absolute Contraindications 1, 4
- Any prior intracranial hemorrhage
- Known structural cerebrovascular lesion (AVM, aneurysm)
- Malignant intracranial neoplasm
- Ischemic stroke within 3 months (except acute stroke <4.5 hours)
- Suspected aortic dissection
- Active bleeding or bleeding diathesis
- Significant head/facial trauma within 3 months
- Intracranial/intraspinal surgery within 2 months
- Severe uncontrolled hypertension (SBP >180 or DBP >110 mm Hg unresponsive to therapy)
Rare but Serious Adverse Events
Angioedema with potential airway compromise can occur, requiring immediate recognition and airway management 9. This is an anaphylactic-type reaction that may present with oropharyngeal swelling, urticaria, and inspiratory stridor shortly after administration.
Pharmacokinetics 3
- Initial half-life: 17-24 minutes
- Terminal half-life: 65-132 minutes
- Clearance: ~105 mL/min (influenced by body weight—10 kg increase results in 9.6 mL/min increase in clearance)
- Volume of distribution: 4.2-6.3 L (approximates plasma volume)
- Liver metabolism is the primary clearance mechanism 2
Real-World Evidence
A large telestroke network study in India (1,389 patients receiving tenecteplase vs. 137 receiving alteplase) demonstrated no significant differences in favorable outcomes, symptomatic intracranial hemorrhage, or mortality, supporting the safety and effectiveness of routine tenecteplase use in real-world practice 8.
Clinical Bottom Line
Tenecteplase represents a practical, effective alternative to alteplase with equivalent efficacy and potentially superior safety profile, particularly advantageous in resource-limited settings or when rapid bolus administration is preferred over prolonged infusion. The weight-based dosing for STEMI and fixed 0.25 mg/kg dosing for stroke (when used off-label) make it straightforward to administer, though strict attention to contraindications—particularly uncontrolled hypertension and recent intracranial pathology—remains essential 1, 6.